The DDR-related gene signature with cell cycle checkpoint function predicts prognosis, immune activity, and chemoradiotherapy response in lung adenocarcinoma

• DOI: 10.1186/s12931-022-02110-w
• Publication Date: 2022-07-15T18:03:35Z
• Authors: Quan Li; Pan Zhang; Huixiao Hu; Hang Huang; Dong Pan; Guangyun Mao; Burong Hu
• Keywords: Lung adenocarcinoma; Cancer prognosis; 0303 health sciences; Lung Neoplasms; RC705-779; Research; Adenocarcinoma of Lung; Cell Cycle Checkpoints; Chemoradiotherapy; Kaplan-Meier Estimate; Prognosis; 3. Good health; Gene Expression Regulation, Neoplastic; Diseases of the respiratory system; 03 medical and health sciences; Gene signature; DNA damage repair; Humans; Cell cycle checkpoint

Abstract Background As a DNA surveillance mechanism, cell cycle checkpoint has recently been discovered to be closely associated with lung adenocarcinoma (LUAD) prognosis. It is also an essential link in the process of DNA damage repair (DDR) that confers resistance to radiotherapy. Whether genes that have both functions play a more crucial role in LUAD prognosis remains unclear.

Methods In this study, DDR-related genes with cell cycle checkpoint function (DCGs) were selected to investigate their effects on the prognosis of LUAD. The TCGA-LUAD cohort and two GEO external validation cohorts (GSE31210 and GSE42171) were performed to construct a prognosis model based on the least absolute shrinkage and selection operator (LASSO) regression. Patients were divided into high-risk and low-risk groups based on the model. Subsequently, the multivariate COX regression was used to construct a prognostic nomogram. The ssGSEA, CIBERSORT algorithm, TIMER tool, CMap database, and IC50 of chemotherapeutic agents were used to analyze immune activity and responsiveness to chemoradiotherapy.

Results 4 DCGs were selected as prognostic signatures, and patients in the high-risk group had a lower overall survival (OS). The lower infiltration levels of immune cells and the higher expression levels of immune checkpoints appeared in the high-risk group. The damage repair pathways were upregulated, and chemotherapeutic agent sensitivity was poor in the high-risk group.

Conclusions The 4-DCGs signature prognosis model we constructed could predict the survival rate, immune activity, and chemoradiotherapy responsiveness of LUAD patients.